文献速递甲状腺疾病

甲状腺髓样癌免疫组化标志物预后价值的系统评价与荟萃分析

The Prognostic Value of Immunohistochemical Biomarkers in Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2025-11-06

该系统评价纳入108项研究、170种免疫组化标志物,样本量11至327例。

要点

  • Ki-67高表达与MTC患者总生存期显著缩短相关。
  • PD-L1阳性与更差的总生存期、复发及侵袭性临床病理特征相关。
  • 多数标志物仅见于单篇报道,高质量验证研究仍缺乏。

核心结论

  • Ki-67和PD-L1阳性是MTC总生存期的显著预后标志物。
  • PD-L1阳性还与复发增加及更侵袭性临床病理特征相关。

研究设计与样本

  • 系统评价与荟萃分析,方案在PROSPERO注册(CRD42023469437)。
  • 检索Embase、MEDLINE(Ovid)和Cochrane数据库,共纳入108项研究,涉及170种独特标志物。
  • 样本量范围为11至327例参与者,主要结局为总生存期(OS)。

主要发现

  • 72%的标志物仅在一篇文章中报道,28%的研究被评为高质量。

关键数值与推荐

  • PD-L1阳性与复发增加及更侵袭性临床病理特征相关。

临床怎么用

  • 可考虑将Ki-67和PD-L1免疫组化纳入MTC风险分层评估。
  • PD-L1阳性结果可为晚期MTC患者抗PD-1/PD-L1免疫治疗研究提供依据。

局限性

  • 多数标志物仅见于单篇报道,证据可重复性有限。
  • 仅28%的研究被评为高质量,研究间质量差异大。
  • Ki-67预后价值的确定性因研究质量差异而不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The prognosis and disease course of medullary thyroid carcinoma (MTC) can vary widely among patients. Effective risk stratification is important for ensuring timely treatment and personalized follow-up. Biomarkers can enhance risk stratification and guide the development of targeted anticancer therapies and imaging techniques. While numerous studies have explored various immunohistochemical biomarkers in MTC, an overview is still lacking. This study aimed to provide a comprehensive overview of immunohistochemical biomarkers and their role in the prognosis of MTC patients, with a primary focus on overall survival (OS). Methods: This review was preregistered in PROSPERO (CRD42023469437). A systematic search was performed using the online medical databases Embase, MEDLINE (Ovid), and Cochrane. Quality was assessed using an adapted scoring system based on the REMARK criteria and the Quality in Prognosis Studies tool. The primary outcome was OS. Secondary outcomes included other types of survival and associations with clinicopathological risk factors and recurrence. Results: Of 2992 studies, 108 were included, investigating 170 unique biomarkers and with sample sizes ranging from 11 to 327 participants. The majority (72%) were reported in only one article. A minority of studies were rated as high quality (28%). Markers of proliferation Ki-67 (Ki-67) and programmed cell death-ligand 1 (PD-L1) were significantly associated with OS (hazard ratio [HR]: 6.67, confidence interval [CI]: 1.43-31.18 and HR: 3.34, CI: 1.18-9.51). Conclusions: Our systematic review provides a comprehensive synthesis of the literature on immunohistochemical biomarkers in MTC and highlights the need for high-quality validation studies. Our meta-analysis confirms the prognostic value of Ki-67, although with varying certainty due to large differences in study quality. Furthermore, we describe the association of PD-L1 positivity with poorer OS, increased recurrence, and more aggressive clinicopathological features, which supports the rationale for further investigating the potential of anti-PD-1/PD-L1 immunotherapy for advanced MTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Schonebaum LE, Oudijk L, Stegenga MT, et al. The Prognostic Value of Immunohistochemical Biomarkers in Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Thyroid. 2025. PMID: 41204672. doi:10.1177/10507256251393208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。